Charles Fuchs was appointed Director of CytomX Therapeutics, Inc. As of November 6, 2026, CytomX Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 27, 2026, naming 1 appointment (Form 8-K, July 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like CytomX Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CytomX Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as CytomX Therapeutics, Inc. files it.
Also on the record for CytomX Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Kynam Capital Management, LP | 9.96% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 3.6% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.4% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 7% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 7.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Kynam Capital Management, LP | 6.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Patrick G. Enright | 7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 4.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Seven Fleet Master Fund LP | 0.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 4.6% of the class | 5%+ stakes | Source |
| April 16, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CytomX Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CytomX Therapeutics, Inc. and the records around it.
CytomX Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: Entera Bio Ltd. (Aug 2026), Mobia Medical, Inc. (May 2026), Veradermics, Incorporated (May 2026)
- Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), Veradermics, Inc (May 2026), CG Oncology, Inc. (Oct 2025)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
Watch CytomX Therapeutics, Inc.
Get an email when CytomX Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CytomX Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CytomX Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CytomX Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 30 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-27 | In | Director | 8-K, 2026-07-27 |
Who leads CytomX Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Charles Fuchs, appointed (filed 2026-07-27).
New leaders reset buying decisions — get the Full Report on CytomX Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at CytomX Therapeutics, Inc., with the record behind each one.
Find candidates like Director at CytomX Therapeutics, Inc.Every change, in the filing's words
Appointed: Charles Fuchs, Director
On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the "Board") of CytomX Therapeutics, Inc. (the "Company"), effective immediately, as a Class II director, with an initial term expiring at the Company's 2029 annual meeting of stockholders.
- Dr. Fuchs will receive the Company's standard non-employee director compensation.
- Upon appointment to the Board, Dr. Fuchs received an option under the Company's 2015 Equity Incentive Plan to purchase 118,000 shares of the Company's common stock with an exercise price equal to the closing price of the Company's common stock on July 24, 2026, the effective date of Dr. Fuchs's appointment.
- The option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the date of appointment to the Board, subject to Dr. Fuchs's continued service to the Company through each applicable vesting date.
- There have not been any transactions since the beginning of the Company's last fiscal year, nor are there any proposed transactions, in which the Company was or is to be a participant involving amounts exceeding $120,000 and in which Dr. Fuchs had or will have a direct or indirect material interest.
Tools for this story
Each opens in a new tab, filled in for CytomX Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.